New approaches to chronic hepatitis B
G Dusheiko, K Agarwal, MK Maini - New England Journal of …, 2023 - Mass Medical Soc
New Approaches to Chronic Hepatitis B | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
The scientific basis of combination therapy for chronic hepatitis B functional cure
Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …
Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)
H You, FS Wang, T Li, X Xu, Y Sun, Y Nan… - Infectious Diseases & …, 2023 - mednexus.org
To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …
[HTML][HTML] A multicenter randomized-controlled trial of nucleos (t) ide analogue cessation in HBeAg-negative chronic hepatitis B
F van Bömmel, K Stein, R Heyne, J Petersen… - Journal of …, 2023 - Elsevier
Background & Aims Nucleos (t) ide analogues (NUCs) are the standard and mostly lifelong
treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely …
treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely …
Toward a functional cure for hepatitis B
ASF Lok - Gut and Liver, 2024 - pmc.ncbi.nlm.nih.gov
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-
α) and nucleos (t) ide analogue (NA), can suppress HBV replication, reverse liver …
α) and nucleos (t) ide analogue (NA), can suppress HBV replication, reverse liver …
New perspectives on development of curative strategies for chronic hepatitis B
A functional cure of chronic hepatitis B defined as sustained hepatitis B surface antigen loss
after finite course of therapy is rarely achieved with current therapy but is the goal of novel …
after finite course of therapy is rarely achieved with current therapy but is the goal of novel …
[HTML][HTML] Past, present, and future of long-term treatment for hepatitis B virus
T Broquetas, JA Carrión - World Journal of Gastroenterology, 2023 - ncbi.nlm.nih.gov
The estimated world prevalence of hepatitis B virus (HBV) infection is 316 million. HBV
infection was identified in 1963 and nowadays is a major cause of cirrhosis and …
infection was identified in 1963 and nowadays is a major cause of cirrhosis and …
[HTML][HTML] Clinical applications of transient elastography
KS Jung, SU Kim - Clinical and molecular hepatology, 2012 - ncbi.nlm.nih.gov
Chronic liver disease represents a major public health problem, accounting for significant
morbidity and mortality worldwide. As prognosis and management depend mainly on the …
morbidity and mortality worldwide. As prognosis and management depend mainly on the …
High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stop** nucleot (s) ide analogue therapy
Abstract Background and Aims Accurate biomarkers to predict outcomes following
discontinuation of nucleos (t) ide analogue (NA) therapy are needed. We evaluated serum …
discontinuation of nucleos (t) ide analogue (NA) therapy are needed. We evaluated serum …
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a …
H Jia, J Mai, M Wu, H Chen, X Li, C Li, J Liu, C Liu… - BMC medicine, 2023 - Springer
Abstract Background Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are
promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral …
promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral …